TY - JOUR
T1 - A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
AU - Margolin, Emmanuel
AU - Schäfer, Georgia
AU - Allen, Joel D.
AU - Gers, Sophette
AU - Woodward, Jeremy
AU - Sutherland, Andrew D.
AU - Blumenthal, Melissa
AU - Meyers, Ann
AU - Shaw, Megan L.
AU - Preiser, Wolfgang
AU - Strasser, Richard
AU - Crispin, Max
AU - Williamson, Anna Lise
AU - Rybicki, Edward P.
AU - Chapman, Ros
N1 - Funding Information:
Funding for the recombinant protein production described in this manuscript was supported in part by core funding provided by the Wellcome Trust [203135/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. EM was supported by scholarship funding from CIDRI Africa. The immunogenicity and challenge work in this manuscript was funded by the UCT Innovation Builder Fund (Project #IB20-14). Further supplementary funding was provided by the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation (grant number: 64815). GS is supported by EDCTP2 programme (Training and Mobility Action TMA2018SF-2446) and receives funding from the NRF, the MRC and the PRF. SARS-CoV-2 isolation and propagation was partially supported by the South African Medical Research Council with funds received from the Department of Science and Innovation (MS and WP), and by the Poliomyelitis Research Foundation (WP, grant 21/81). ADS was supported by a bursary from the Poliomyelitis Research Foundation (grant 21/45). RS was supported by the Austrian Science Fund (FWF) Project P31920-B32. MB holds a ACSR Young Investigator Pilot Award and has received funding from the NRF and the Oppenheimer Memorial Trust. This work was also supported by the International AIDS Vaccine Initiative (IAVI) through grant INV- 008352/OPP1153692 funded by the Bill and Melinda Gates Foundation (MC). Acknowledgments
Publisher Copyright:
Copyright © 2023 Margolin, Schäfer, Allen, Gers, Woodward, Sutherland, Blumenthal, Meyers, Shaw, Preiser, Strasser, Crispin, Williamson, Rybicki and Chapman.
PY - 2023
Y1 - 2023
N2 - Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
AB - Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
KW - SARS-CoV-2
KW - challenge
KW - glycoprotein
KW - glycosylation
KW - immunogenicity
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85150926052&partnerID=8YFLogxK
U2 - 10.3389/fpls.2023.1146234
DO - 10.3389/fpls.2023.1146234
M3 - Article
AN - SCOPUS:85150926052
SN - 1664-462X
VL - 14
JO - Frontiers in Plant Science
JF - Frontiers in Plant Science
M1 - 1146234
ER -